Bcl-2 Antibody (5K140): sc-70411

Bcl-2 Antibody (5K140) is a mouse monoclonal IgG1 antibody that detects Bcl-2 in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Bcl-2 is a crucial regulator of apoptosis, playing a significant role in cell survival and tissue homeostasis. Anti-Bcl-2 antibody (5K140) targets this anti-apoptotic, membrane-associated oncoprotein that prevents unnecessary cell death, essential for proper development and protection against foreign pathogens. Bcl-2 achieves protective effects by interacting with other members of the Bcl-2 family, including both death suppressors like Bcl-xL and Mcl-1, and death agonists such as Bax and Bak. Bcl-2′s ability to stabilize the mitochondrial membrane is particularly important, as Bcl-2 interferes with the activation of the cytochrome c/Apaf-1 pathway, thereby preventing the release of pro-apoptotic factors. Additionally, Bcl-2 can undergo post-translational modifications, including phosphorylation, which can further modulate function and interactions. Dysregulation of Bcl-2, often due to mutations in the Bcl-2 gene, is implicated in various cancers, highlighting the importance of Bcl-2 in maintaining normal physiological cell death mechanisms. Bcl-2 monoclonal antibody (5K140) is an invaluable tool for researchers studying apoptosis and its implications in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Bcl-2 Antibody (5K140) References:

1. In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.  |  Mologni, L., et al. 1999. Biochem Biophys Res Commun. 264: 537-43. PMID: 10529398
2. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.  |  Miyake, H., et al. 1999. J Urol. 162: 2176-81. PMID: 10569615
3. Sodium butyrate modulates p53 and Bcl-2 expression in human retinoblastoma cell lines.  |  Madigan, MC., et al. 1999. Oncol Res. 11: 331-7. PMID: 10757447
4. Involvement of histone hypoacetylation in Ni2+-induced bcl- 2 down-regulation and human hepatoma cell apoptosis.  |  Kang, J., et al. 2004. J Biol Inorg Chem. 9: 713-23. PMID: 15235941
5. Activated JNK brings about accelerated apoptosis of Bcl-2-overexpressing C6 glioma cells on treatment with tamoxifen.  |  Moodbidri, MS. and Shirsat, NV. 2005. J Neurochem. 92: 1-9. PMID: 15606891
6. Intronic single-nucleotide polymorphisms in Bcl-2 are associated with chronic obstructive pulmonary disease severity.  |  Sata, M., et al. 2007. Respirology. 12: 34-41. PMID: 17207023
7. P53 and bcl-2 assessment in serous ovarian carcinoma.  |  Palmer, JE., et al. 2008. Int J Gynecol Cancer. 18: 241-8. PMID: 18334006
8. The survival of heavy ion-irradiated Bcl-2 overexpressing radioresistant tumor cells and their progeny.  |  Hamada, N., et al. 2008. Cancer Lett. 268: 76-81. PMID: 18450372
9. The interplay between cell death signaling pathways in the heart.  |  Biala, AK. and Kirshenbaum, LA. 2014. Trends Cardiovasc Med. 24: 325-31. PMID: 25263458
10. LncRNA GOLGA2P10 is induced by PERK/ATF4/CHOP signaling and protects tumor cells from ER stress-induced apoptosis by regulating Bcl-2 family members.  |  Wu, MZ., et al. 2020. Cell Death Dis. 11: 276. PMID: 32332695

The preferred Bcl-2 antibody is Bcl-2 Antibody (C-2): sc-7382.